

Remarks

Currently Claims 1-8, 12 and 14-18 are pending. Claims 9-11 and 13 are canceled.

Claims 1-8, and 12 are amended herein. Claim 1 is amended to change “represents” to “is” or “are.” Claims 1 and 8 are amended to add subscripts in the formulas. Claims 3-5 and 12 are amended to remove multiple dependencies for the purpose of reducing claim fees. Claims 2 and 5-7 are amended to remove parenthetical clauses. The amendments do not narrow the scope of the claims and are not being made for reasons of patentability. No new matter is added.

New claims 14-18 are added. New claims 14-15 recite embodiments encompassed by original claims 2 and 5, respectively. Original claim 13 is rewritten as new claims 18-20. No new matter is added.

The specification has been amended to recite related applications and to provide an abstract on a separate page. No new matter is added.

Entry of the foregoing amendments is respectfully requested.

Applicants respectfully submit that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is invited to contact the undersigned at (919) 483-8222, to discuss this case, if desired.

Respectfully submitted,



Lorie Ann Morgan  
Attorney for Applicants  
Registration No. 38,181

Date: 3 January, 2005  
GlaxoSmithKline Inc.  
Five Moore Drive, PO Box 13398  
Research Triangle Park  
North Carolina 27709  
(919) 483-8222  
fax: (919) 483-7988  
Lorie.A.Morgan@gsk.com